Chronic lymphocytic leukemia radiogenicity: a systematic review

被引:18
作者
Silver, Sharon R.
Hiratzka, Shannon L.
Schubauer-Berigan, Mary K.
Daniels, Robert D.
机构
[1] NIOSH, DSHEFS, Cincinnati, OH 45226 USA
[2] Constella Grp LLC, Durham, NC USA
关键词
chronic lymphocytic leukemia; ionizing radiation; radiogenicity;
D O I
10.1007/s10552-007-9048-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic lymphocytic leukemia (CLL) is generally considered to be non-radiogenic and is excluded from several programs that compensate workers for illnesses resulting from occupational exposures. Questions about whether this exclusion is justified prompted a Congressional mandate to the National Institute for Occupational Safety and Health (NIOSH) to, further, examine the radiogenicity of CLL. This study revisits the question of CLL radiogenicity by examining epidemiologic evidence from occupationally and medically-exposed populations. A systematic review of radiation-exposed cohorts was conducted to investigate the association between radiation and CLL. Exploratory power calculations for a pooled occupational study were performed to examine the feasibility of assessing CLL radiogenicity epidemiologically. There is a bias against reporting CLL results, because of the disease's presumed non-radiogenicity. In medical cohort studies that provide risk estimates for CLL, risk is elevated, though non-significantly, in almost all studies with more than 15 years average follow-up. The results of occupational studies are less consistent. Studies with adequate follow-up time and power are needed to better understand CLL radiogenicity. Power analyses show that a pooled study might detect risk on the order of radiation induced non-CLL leukemia, but is unlikely to detect smaller risks.
引用
收藏
页码:1077 / 1093
页数:17
相关论文
共 50 条
  • [31] Familial chronic lymphocytic leukemia
    Goldin, Lynn R.
    Slager, Susan L.
    Caporaso, Neil E.
    CURRENT OPINION IN HEMATOLOGY, 2010, 17 (04) : 350 - 355
  • [32] Rituximab in chronic lymphocytic leukemia
    James, Danelle F.
    Kipps, Thomas J.
    ADVANCES IN THERAPY, 2011, 28 (07) : 534 - 554
  • [33] Pentostatin in chronic lymphocytic leukemia
    Sauter, Craig
    Lamanna, Nicole
    Weiss, Mark A.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2008, 4 (09) : 1217 - 1222
  • [34] Rituximab in chronic lymphocytic leukemia
    Danelle F. James
    Thomas J. Kipps
    Advances in Therapy, 2011, 28 : 534 - 554
  • [35] Biclonal chronic lymphocytic leukemia
    Hsi, ED
    Hoeltge, G
    Tubbs, RR
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 113 (06) : 798 - 804
  • [36] Epigenetics and chronic lymphocytic leukemia
    Yu, Margaret K.
    AMERICAN JOURNAL OF HEMATOLOGY, 2006, 81 (11) : 864 - 869
  • [37] Familial chronic lymphocytic leukemia
    Houlston R.S.
    Catovsky D.
    Current Hematologic Malignancy Reports, 2008, 3 (4) : 221 - 225
  • [38] Obinutuzumab in chronic lymphocytic leukemia
    Dupuis, Jehan
    FUTURE ONCOLOGY, 2015, 11 (18) : 2503 - 2513
  • [39] Autoimmunity in chronic lymphocytic leukemia
    Ward J.H.
    Current Treatment Options in Oncology, 2001, 2 (3) : 253 - 257
  • [40] Immunogenetics of chronic lymphocytic leukemia
    Patkar, Nikhil
    Rabade, Nikhil
    Kadam, Pratibha Amare
    Mishra, Falguni
    Muranjan, Aditi
    Tembhare, Prashant
    Chaudhary, Shruti
    Joshi, Swapnali
    Jain, Hasmukh
    Dangi, Uma
    Bagal, Bhausaheb
    Khattry, Navin
    Menon, Hari
    Gujral, Sumeet
    Sengar, Manju
    Subramanian, P. G.
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2017, 60 (01) : 38 - 42